GKOS · NYSE
Glaukos Corporation
$213.38 +3.40 (+1.91%)
Company overview
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, and iStent inject W micro-bypass stents that enhance aqueous humor outflow, inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three-stent product designed for use as a standalone procedure in patients with refractory glaucoma, and iDose TR, a targeted injectable implant based on its micro-scale device platform designed to deliver therapeutic levels of medication. The company markets its products through a direct sales organization as well as through distributors in the United States and internationally.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NYSE
- Market cap
- $12.6B
- Employees
- 995
- Headquarters
- Aliso Viejo, CA
- Website
- glaukos.com
- CEO
- Thomas William Burns
- Listed
- June 25, 2015
- P/E
- -65.05
- Dividend yield
- 0.00%
Company financials
- Revenue
- $551M
- Gross profit
- $431M
- Operating income
- -$85.9M
- EBITDA
- -$40M
- Net income
- -$189M
- EPS
- -$3.28
- Total assets
- $893M
- Total debt
- $103M
- Gross margin
- 78.08%
- Net margin
- -34.34%
- Earnings yield
- -1.54%
Showing FY 2025
GKOS
1D
NYSE
O181.94H187.94L174.75C181.47+0.30 (+0.17%)Vol516.76K